TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

10 5月 2024 17:40:49 条件 Nasdaq GlobeNewswire

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

01 5月 2024 08:05:00 条件 Nasdaq GlobeNewswire

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

26 4月 2024 09:23:59 条件 Nasdaq GlobeNewswire

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

11 4月 2024 08:05:00 条件 Nasdaq GlobeNewswire

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

03 4月 2024 08:05:00 条件 Nasdaq GlobeNewswire

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

28 3月 2024 08:05:00 条件 Nasdaq GlobeNewswire